In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping ...

Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...

With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

The appointments are “a direct response to where our clients need us most,” Michael Maslansky, CEO of m+p, said in a ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

Bristol Myers Squibb, by way of its RayzeBio unit, has taken a big step in furthering its commitment to radiopharmaceuticals, ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.

On Wednesday, the U.S. Court of Appeals for the Fifth Circuit affirmed (PDF) a previous ruling in district court rebuffing ...

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...